Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria

被引:81
作者
Hong, Seung Baek [1 ,2 ,5 ]
Lee, Seung Soo [1 ,2 ]
Kim, Jin Hee [1 ,2 ]
Kim, Hyoung Jung [1 ,2 ]
Byun, Jae Ho [1 ,2 ]
Hong, Seung Mo [3 ]
Song, Ki-Byung [4 ]
Kim, Song Cheol [4 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, 88 Olymp Ro,43 Gil, Seoul 138736, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Res Inst Radiol, 88 Olymp Ro,43 Gil, Seoul 138736, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 88 Olymp Ro,43 Gil, Seoul 138736, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, 88 Olymp Ro,43 Gil, Seoul 138736, South Korea
[5] Pusan Natl Univ Hosp, Dept Radiol, Pusan, South Korea
基金
新加坡国家研究基金会;
关键词
ROW COMPUTED-TOMOGRAPHY; ADENOCARCINOMA; RESECTION; STAGE; CONSENSUS; SURVIVAL; SURGERY; METAANALYSIS; ANGIOGRAPHY; CARCINOMA;
D O I
10.1148/radiol.2018180628
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To evaluate the diagnostic performance of CT in the determination of pancreatic cancer resectability according to the National Comprehensive Cancer Network (NCCN) criteria to predict R0 resection. Materials and Methods: Structured reports of pancreatic CT clinically prepared by board-certified abdominal radiologists from January 2014 to March 2017 were retrospectively reviewed to assess resectability (resectable, borderline resectable, or unresectable) according to NCCN criteria (version 1.2017) in 616 patients (369 men, 247 women; mean age, 63 years 6 10 [standard deviation]) with pancreatic cancer. Negative resection margin (R0) rates were assessed based on CT resectability status in patients who underwent upfront surgery. R0 resection-associated factors were identified by using logistic regression analysis. Results: In 371 patients who underwent surgery, R0 resection rates were 73% (171 of 235), 55% (57 of 104), and 16% (five of 32) for resectable, borderline resectable, and unresectable disease, respectively (P <.001). At multivariable analysis, tumor diameter larger than 4 cm (P <.001) and abutment to the portomesenteric vein (P <.001) were significantly associated with marginpositive resection in patients with resectable disease at CT. R0 resection rates were 80% (123 of 154) for resectable disease without portomesenteric vein abutment, 59% (48 of 81) for resectable disease with portomesenteric vein abutment, 83% (57 of 69) for resectable disease 2 cm or smaller, and 29% (five of 17) for tumors larger than 4 cm. Conclusion: CT resectability is used to stratify patients with pancreatic cancer according to the possibility of R0 resection. Larger tumor size and tumor abutment to the portomesenteric vein are associated with margin-positive resection in patients with resectable pancreatic cancer. (C) RSNA, 2018
引用
收藏
页码:710 / 718
页数:9
相关论文
共 34 条
[1]   Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association [J].
Al-Hawary, Mahmoud M. ;
Francis, Isaac R. ;
Chari, Suresh T. ;
Fishman, Elliot K. ;
Hough, David M. ;
Lu, David S. ;
Macari, Michael ;
Megibow, Alec J. ;
Miller, Frank H. ;
Mortele, Koenraad J. ;
Merchant, Nipun B. ;
Minter, Rebecca M. ;
Tamm, Eric P. ;
Sahani, Dushyant V. ;
Simeone, Diane M. .
GASTROENTEROLOGY, 2014, 146 (01) :291-+
[2]   Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies [J].
Andriulli, Angelo ;
Festa, Virginia ;
Botteri, Edoardo ;
Valvano, Maria R. ;
Koch, Maurizio ;
Bassi, Claudio ;
Maisonneuve, Patrick ;
Di Sebastiano, Pierluigi .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (05) :1644-1662
[3]  
Badger S A, 2010, Ulster Med J, V79, P70
[4]   Justifying vein resection with pancreatoduodenectomy [J].
Barreto, Savio G. ;
Windsor, John A. .
LANCET ONCOLOGY, 2016, 17 (03) :E118-E124
[5]   National failure to operate on early stage pancreatic cancer [J].
Bilimoria, Karl Y. ;
Bentrem, David J. ;
Ko, Clifford Y. ;
Stewart, Andrew K. ;
Winchester, David P. ;
Talamonti, Mark S. .
ANNALS OF SURGERY, 2007, 246 (02) :173-180
[6]   Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement [J].
Callery, Mark P. ;
Chang, Kenneth J. ;
Fishman, Elliot K. ;
Talamonti, Mark S. ;
Traverso, L. William ;
Linehan, David C. .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) :1727-1733
[7]   Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease [J].
Cassinotto, Christophe ;
Dohan, Anthony ;
Zogopoulos, George ;
Chiche, Laurence ;
Laurent, Christophe ;
Sa-Cunha, Antonio ;
Cuggia, Adeline ;
Reinhold, Caroline ;
Gallix, Benoit .
EUROPEAN JOURNAL OF RADIOLOGY, 2017, 95 :33-38
[8]   Locally Advanced Pancreatic Adenocarcinoma: Reassessment of Response with CT after Neoadjuvant Chemotherapy and Radiation Therapy [J].
Cassinotto, Christophe ;
Mouries, Amaury ;
Lafourcade, Jean-Pierre ;
Terrebonne, Eric ;
Belleannee, GeneviSve ;
Blanc, Jean-Frederic ;
Lapuyade, Bruno ;
Vendrely, Veronique ;
Laurent, Christophe ;
Chiche, Laurence ;
Wagner, Tristan ;
Sa-Cunha, Antonio ;
Gaye, Delphine ;
Trillaud, Herve ;
Laurent, Francois ;
Montaudon, Michel .
RADIOLOGY, 2014, 273 (01) :108-116
[9]   Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study [J].
De Angelis, Roberta ;
Sant, Milena ;
Coleman, Michel P. ;
Francisci, Silvia ;
Baili, Paolo ;
Pierannunzio, Daniela ;
Trama, Annalisa ;
Visser, Otto ;
Brenner, Hermann ;
Ardanaz, Eva ;
Bielska-Lasota, Magdalena ;
Engholm, Gerda ;
Nennecke, Alice ;
Siesling, Sabine ;
Berrino, Franco ;
Capocaccia, Riccardo .
LANCET ONCOLOGY, 2014, 15 (01) :23-34
[10]  
Edge SB, 2010, AJCC CANER STAGING M